Form 10-K Arcturus Therapeutics For: Dec 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall St dips after AI-led selloff; SpaceX worries hit telecoms
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude hits more than five-month high on Houthi-Saudi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
- AMD shares fall amid AI chip sector selloff
- JetBlue shares fall amid American results, fuel cost concerns
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Nokia shares fall despite earnings beat on cash flow concerns
Arcturus Therapeutics (ARCT) PT Lowered to $65 at Leerink Partners
March 7, 2025 5:47 AM ESTLeerink Partners analyst Lili Nsongo lowered the price target on Arcturus Therapeutics (NASDAQ: ARCT) to $65.00 (from $70.00) while maintaining a Outperform rating.
The analyst comments "Bottom Line: Today after close, ARCT reported FY24 earnings and provided a pipeline update. In the partnered vaccine... More



